Cynata is focussed on the development and commercialisation of a proprietary|Dr Kilian Kelly,Chief Executive Officer,Cynata Therapeutics Ltd 00:10:00
Dr Kilian Kelly has over 20 years’ experience in biopharmaceutical research and development. He joined the Company in March 2014 as Vice President, Product Development, and was promoted to Chief Operating Officer in May 2019, before taking on the role of CEO & MD in July 2023. His previous appointments include Senior Director, Drug Development at Biota Pharmaceuticals (NASDAQ: BOTA), Vice President, Regulatory and Clinical at Mesoblast Limited (ASX:MSB), and positions with Kendle International (now Syneos Health
